Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01048255 · ClinicalTrials.gov registry record · Phase 2
Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01048255 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 60 participants.
The verdict
NCT01048255, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of VX-765 in subjects with Treatment-resistant Partial Epilepsy
Interventions
- DRUG VX-765
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01048255
The ClinicalTrials.gov registry entry for NCT01048255 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VX-765 is the first listed.
NCT01048255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01048255 about?
NCT01048255 is a clinical study titled "Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy". The purpose of this study is to determine the safety, tolerability, and efficacy of VX-765 in subjects with Treatment-resistant Partial Epilepsy
What is the current status of trial NCT01048255?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2010-01. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01048255?
The interventions under investigation include: VX-765 (DRUG).
Who is sponsoring clinical trial NCT01048255?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.